Drug Information Association Logo
« Back to Listing

Evaluating Potential Contribution of Social Media to Postmarketing Medication Safety Surveillance

Track:
Clinical Safety and Pharmacovigilance

Day & Time:
June 17, 3:30PM - 5:00PM (Pacific Standard Time)

Session Number:
299A

Room Number:
6C

Level:
Intermediate

Type:
Session

Title:
Evaluating Potential Contribution of Social Media to Postmarketing Medication Safety Surveillance

Chair(s):
Preciosa M. Coloma, MD, PhD, MSc, RPh
Assistant Professor; Research Collaborator, EMIF
Erasmus MC University Medical Center, Netherlands

Description:
Social media is a phenomenon that is increasingly becoming influential in health care. In this session, we will give an overview and evaluation of the potential contribution of social media data sources for postmarketing drug safety surveillance.

Learning Objective(s):
Provide an overview of the potential usefulness of various social media data sources for postmarketing medication safety surveillance; Discuss various approaches to evaluating the potential contribution of social media data sources to postmarketing medication safety surveillance.

Presentation(s) & Speaker(s):
Social Media and Pharmacovigilance
Stella Stergiopoulos
Senior Project Manager
Tufts Center for the Study of Drug Development, United States

Evaluating Medication Safety and Effectiveness Using Patient-Generated Data
Sally Okun, RN
Vice President, Advocacy, Policy and Patient Safety
PatientsLikeMe, United States

Reinventing Safety: What Will It Take to Realize the Promise of Digital Pharmacovigilance and Social Media?
Michael A. Ibara, PharmD
Head of Business Development Coordination and Innovation, WW Safety & Regulatory
Pfizer Inc, United States